Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK
Abstract As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, ato...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-47176-w |
| _version_ | 1827291484274032640 |
|---|---|
| author | Jiyeon Oh Myeongcheol Lee Minji Kim Hyeon Jin Kim Seung Won Lee Sang Youl Rhee Ai Koyanagi Lee Smith Min Seo Kim Hayeon Lee Jinseok Lee Dong Keon Yon |
| author_facet | Jiyeon Oh Myeongcheol Lee Minji Kim Hyeon Jin Kim Seung Won Lee Sang Youl Rhee Ai Koyanagi Lee Smith Min Seo Kim Hayeon Lee Jinseok Lee Dong Keon Yon |
| author_sort | Jiyeon Oh |
| collection | DOAJ |
| description | Abstract As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy. We used nationwide claims-based cohorts in South Korea (K-CoV-N; n = 836,164; main cohort) and Japan (JMDC; n = 2,541,021; replication cohort A) and the UK Biobank cohort (UKB; n = 325,843; replication cohort B) after 1:5 propensity score matching. Among the 836,164 individuals in the main cohort (mean age, 50.25 years [SD, 13.86]; 372,914 [44.6%] women), 147,824 were infected with SARS-CoV-2 during the follow-up period (2020−2021). The risk of developing allergic diseases, beyond the first 30 days of diagnosis of COVID-19, significantly increased (HR, 1.20; 95% CI, 1.13−1.27), notably in asthma (HR, 2.25; 95% CI, 1.80−2.83) and allergic rhinitis (HR, 1.23; 95% CI, 1.15−1.32). This risk gradually decreased over time, but it persisted throughout the follow-up period (≥6 months). In addition, the risk increased with increasing severity of COVID-19. Notably, COVID-19 vaccination of at least two doses had a protective effect against subsequent allergic diseases (HR, 0.81; 95% CI, 0.68−0.96). Similar findings were reported in the replication cohorts A and B. Although the potential for misclassification of pre-existing allergic conditions as incident diseases remains a limitation, ethnic diversity for evidence of incident allergic diseases in post-COVID-19 condition has been validated by utilizing multinational and independent population-based cohorts. |
| first_indexed | 2024-04-24T12:37:48Z |
| format | Article |
| id | doaj.art-e4c60b6beda2409d9ed7dc498e649221 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-04-24T12:37:48Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-e4c60b6beda2409d9ed7dc498e6492212024-04-07T11:24:33ZengNature PortfolioNature Communications2041-17232024-04-0115111010.1038/s41467-024-47176-wIncident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UKJiyeon Oh0Myeongcheol Lee1Minji Kim2Hyeon Jin Kim3Seung Won Lee4Sang Youl Rhee5Ai Koyanagi6Lee Smith7Min Seo Kim8Hayeon Lee9Jinseok Lee10Dong Keon Yon11Department of Medicine, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University College of MedicineDepartment of Precision Medicine, Sungkyunkwan University School of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University College of MedicineResearch and Development Unit, Parc Sanitari Sant Joan de DeuCentre for Health, Performance and Wellbeing, Anglia Ruskin UniversityMedical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of MIT and HarvardCenter for Digital Health, Medical Science Research Institute, Kyung Hee University College of MedicineDepartment of Biomedical Engineering, Kyung Hee UniversityDepartment of Medicine, Kyung Hee University College of MedicineAbstract As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy. We used nationwide claims-based cohorts in South Korea (K-CoV-N; n = 836,164; main cohort) and Japan (JMDC; n = 2,541,021; replication cohort A) and the UK Biobank cohort (UKB; n = 325,843; replication cohort B) after 1:5 propensity score matching. Among the 836,164 individuals in the main cohort (mean age, 50.25 years [SD, 13.86]; 372,914 [44.6%] women), 147,824 were infected with SARS-CoV-2 during the follow-up period (2020−2021). The risk of developing allergic diseases, beyond the first 30 days of diagnosis of COVID-19, significantly increased (HR, 1.20; 95% CI, 1.13−1.27), notably in asthma (HR, 2.25; 95% CI, 1.80−2.83) and allergic rhinitis (HR, 1.23; 95% CI, 1.15−1.32). This risk gradually decreased over time, but it persisted throughout the follow-up period (≥6 months). In addition, the risk increased with increasing severity of COVID-19. Notably, COVID-19 vaccination of at least two doses had a protective effect against subsequent allergic diseases (HR, 0.81; 95% CI, 0.68−0.96). Similar findings were reported in the replication cohorts A and B. Although the potential for misclassification of pre-existing allergic conditions as incident diseases remains a limitation, ethnic diversity for evidence of incident allergic diseases in post-COVID-19 condition has been validated by utilizing multinational and independent population-based cohorts.https://doi.org/10.1038/s41467-024-47176-w |
| spellingShingle | Jiyeon Oh Myeongcheol Lee Minji Kim Hyeon Jin Kim Seung Won Lee Sang Youl Rhee Ai Koyanagi Lee Smith Min Seo Kim Hayeon Lee Jinseok Lee Dong Keon Yon Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK Nature Communications |
| title | Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK |
| title_full | Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK |
| title_fullStr | Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK |
| title_full_unstemmed | Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK |
| title_short | Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK |
| title_sort | incident allergic diseases in post covid 19 condition multinational cohort studies from south korea japan and the uk |
| url | https://doi.org/10.1038/s41467-024-47176-w |
| work_keys_str_mv | AT jiyeonoh incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT myeongcheollee incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT minjikim incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT hyeonjinkim incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT seungwonlee incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT sangyoulrhee incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT aikoyanagi incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT leesmith incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT minseokim incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT hayeonlee incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT jinseoklee incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk AT dongkeonyon incidentallergicdiseasesinpostcovid19conditionmultinationalcohortstudiesfromsouthkoreajapanandtheuk |